How folate metabolism affects colorectal cancer development and treatment; a story of heterogeneity and pleiotropy

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 224-230

  Jennings, Barbara Anne ^a   Willis, Gavin ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Colorectal cancer; Folate metabolism; Pharmacogenetics

Indexed keywords

FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; TUMOR MARKER; CAPECITABINE; DEOXYCYTIDINE; FOLIC ACID ANTAGONIST; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN; THYMIDYLATE SYNTHASE;

CANCER THERAPY; CARCINOGENESIS; COLORECTAL CANCER; DISEASE MARKER; FOLIC ACID METABOLISM; GENE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; MTHFR GENE; NONHUMAN; PHARMACOGENETICS; PLEIOTROPY; PREDICTION; SHORT SURVEY; VITAMIN METABOLISM; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; FOLIC ACID DEFICIENCY; GENETICS; METABOLISM; MUTATION; PATHOLOGY;

COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONISTS; FOLIC ACID DEFICIENCY; GENETIC HETEROGENEITY; GENETIC PLEIOTROPY; GENETIC VARIATION; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUTATION; THYMIDYLATE SYNTHASE;

EID: 84920186191     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.02.024     Document Type: Review

References (71)

1. Pharmacogenetic testing to predict serious toxicity from 5-fluorouracil (5-FU) for patients administered 5-FU-based chemotherapy for cancer, Technology Evaluation Center Assessment Program. Executive summary, 24 (2010) 1-3.
2. Afzal S., Gusella M., Jensen S.A., Vainer B., Vogel U., Andersen J.T., Brodbaek K., Petersen M., Jimenez-Solem E., Adleff V., Budai B., Hitre E., Lang I., Orosz E., Bertolaso L., Barile C., Padrini R., Kralovanszky J., Pasini F., Poulsen H.E. The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer. Pharmacogenomics 2011, 12:1257-1267.
3. Afzal S., Gusella M., Vainer B., Vogel U.B., Andersen J.T., Broedbaek K., Petersen M., Jimenez-Solem E., Bertolaso L., Barile C., Padrini R., Pasini F., Jensen S.A., Poulsen H.E. Combinations of polymorphisms in genes involved in the 5-fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients. Clin. Cancer Res. 2011, 17:3822-3829.
4. Angier R.B., Boothe J.H., Hutchings B.L., Mowat J.H., Semb J., Stokstad E.L., Subbarow Y., Waller C.W., Cosulich D.B., Fahrenbach M.J., Hultquist M.E., Kuh E., Northey E.H., Seeger D.R., Sickels J.P., Smith J.M. Synthesis of a compound identical with the L. Casei factor isolated from liver. Science 1945, 102:227-228.
5. Braun M.S., Richman S.D., Thompson L., Daly C.L., Meade A.M., Adlard J.W., Allan J.M., Parmar M.K.B., Quirke P., Seymour M.T. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J. Clin. Oncol. 2009, 27:5519-5528.
6. Cassidy J., Twelves C., Van Cutsem E., Hoff P., Bajetta E., Boyer M., Bugat R., Burger U., Garin A., Graeven U., McKendric J., Maroun J., Marshall J., Osterwalder B., Perez-Manga G., Rosso R., Rougier P., Schilsky R.L., Capecitabine G. Colorectal cancer study, First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann. Oncol. 2002, 13:566-575.
7. Castillo-Lancellotti C., Tur J.A., Uauy R. Impact of folic acid fortification of flour on neural tube defects: a systematic review. Public Health Nutr. 2013, 16:901-911.
8. Caudle K.E., Thorn C.F., Klein T.E., Swen J.J., McLeod H.L., Diasio R.B., Schwab M. Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin. Pharmacol. Ther. 2013, 94:640-645.
9. Cohen V., Panet-Raymond V., Sabbaghian N., Morin I., Batist G., Rozen R. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin. Cancer Res. 2003, 9:1611-1615.
10. Cole B.F., Baron J.A., Sandler R.S., Haile R.W., Ahnen D.J., Bresalier R.S., McKeown-Eyssen G., Summers R.W., Rothstein R.I., Burke C.A., Snover D.C., Church T.R., Allen J.I., Robertson D.J., Beck G.J., Bond J.H., Byers T., Mandel J.S., Mott L.A., Pearson L.H., Barry E.L., Rees J.R., Marcon N., Saibil F., Ueland P.M., Greenberg E.R. G. polyp prevention study, folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA: J. Am. Med. Assoc. 2007, 297:2351-2359.
11. Dallas N.A., Xia L., Fan F., Gray M.J., Gaur P., van Buren G., Samuel S., Kim M.P., Lim S.J., Ellis L.M. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 2009, 69:1951-1957.
12. Daly L.E., Kirke P.N., Molloy A., Weir D.G., Scott J.M. Folate levels and neural tube defects. Implications for prevention. JAMA: J. Am. Med. Assoc. 1995, 274:1698-1702.
13. de Bock C.E., Garg M.B., Scott N., Sakoff J.A., Scorgie F.E., Ackland S.P., Lincz L.F. Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo. Pharmacogenomics J. 2011, 11:307-314.
14. De S., Michor F. DNA secondary structures and epigenetic determinants of cancer genome evolution. Nat. Struct. Mol. Biol. 2011, 18:950-955.
15. Ding W., Zhou D.L., Jiang X., Lu L.S. Methionine synthase A2756G polymorphism and risk of colorectal adenoma and cancer: evidence based on 27 studies. PLoS One 2013, 8:e60508.
16. Domingo E., Ramamoorthy R., Oukrif D., Rosmarin D., Presz M., Wang H., Pulker H., Lockstone H., Hveem T., Cranston T., Danielsen H., Novelli M., Davidson B., Xu Z.Z., Molloy P., Johnstone E., Holmes C., Midgley R., Kerr D., Sieber O., Tomlinson I. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. J. Pathol. 2013, 229:441-448.
17. Duthie S.J. Folate and cancer: how DNA damage, repair and methylation impact on colon carcinogenesis. J. Inherit. Metab. Dis. 2011, 34:101-109.
18. Ebbing M., Bonaa K.H., Nygard O., Arnesen E., Ueland P.M., Nordrehaug J.E., Rasmussen K., Njolstad I., Refsum H., Nilsen D.W., Tverdal A., Meyer K., Vollset S.E. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA: J. Am. Med. Assoc. 2009, 302:2119-2126.
19. N.I.f.H.a.C. Excellence, (Anaemia-B12 and folate deficiency), National Institute for Health and Care Excellence, London, 2013.
20. Fernandez-Rozadilla C., Cazier J.B., Moreno V., Crous-Bou M., Guino E., Duran G., Lamas M.J., Lopez R., Candamio S., Gallardo E., Pare L., Baiget M., Paez D., Lopez-Fernandez L.A., Cortejoso L., Garcia M.I., Bujanda L., Gonzalez D., Gonzalo V., Rodrigo L., Rene J.M., Jover R., Brea-Fernandez A., Andreu M., Bessa X., Llor X., Xicola R., Palles C., Tomlinson I., Castellvi-Bel S., Castells A., Ruiz-Ponte C., Carracedo A. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. Pharmacogenomics J. 2013, 13:209-217.
21. Finglas P.M., de Meer K., Molloy A., Verhoef P., Pietrzik K., Powers H.J., van der Straeten D., Jagerstad M., Varela-Moreiras G., van Vliet T., Havenaar R., Buttriss J., Wright A.J. Research goals for folate and related B vitamin in Europe. Eur. J. Clin. Nutr. 2006, 60:287-294.
22. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., Boers G.J., den Heijer M., Kluijtmans L.A., van den Heuvel L.P., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 1995, 10:111-113.
23. Ghosh S., Hossain M.Z., Borges M., Goggins M.G., Ingersoll R.G., Eshleman J.R., Klein A.P., Kern S.E. Analysis of polymorphisms and haplotype structure of the human thymidylate synthase genetic region: a tool for pharmacogenetic studies. PLoS One 2012, 7:e34426.
24. Ghosh S., Winter J.M., Patel K., Kern S.E. Reexamining a proposal: thymidylate synthase 5'-untranslated region as a regulator of translation efficiency. Cancer Biol. Ther. 2011, 12:750-755.
25. Gusella M., Frigo A.C., Bolzonella C., Marinelli R., Barile C., Bononi A., Crepaldi G., Menon D., Stievano L., Toso S., Pasini F., Ferrazzi E., Padrini R. Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br. J. Cancer 2009, 100:1549-1557.
26. Herbert V., Zalusky R. Interrelations of vitamin B12 and folic acid metabolism: folic acid clearance studies. J. Clin. Invest. 1962, 41:1263-1276.
27. Hirsch S., Sanchez H., Albala C., de la Maza M.P., Barrera G., Leiva L., Bunout D. Colon cancer in Chile before and after the start of the flour fortification program with folic acid. Eur. J. Gastroenterol. Hepatol. 2009, 21:436-439.
28. Horie N., Aiba H., Oguro K., Hojo H., Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 1995, 20:191-197.
29. Jennings B.A., Kwok C.S., Willis G., Matthews V., Wawruch P., Loke Y.K. Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis. Pharmacogenet. Genomics 2012, 22:290-304.
30. Jennings B.A., Loke Y.K., Skinner J., Keane M., Chu G.S., Turner R., Epurescu D., Barrett A., Willis G. Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines. PLoS One 2013, 8:e78053.
31. Jover R., Nguyen T.P., Perez-Carbonell L., Zapater P., Paya A., Alenda C., Rojas E., Cubiella J., Balaguer F., Morillas J.D., Clofent J., Bujanda L., Rene J.M., Bessa X., Xicola R.M., Nicolas-Perez D., Castells A., Andreu M., Llor X., Boland C.R., Goel A. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 2011, 140:1174-1181.
32. Kawakami K., Watanabe G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res. 2003, 63:6004-6007.
33. Koi M., Umar A., Chauhan D.P., Cherian S.P., Carethers J.M., Kunkel T.A., Boland C.R. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res. 1994, 54:4308-4312.
34. Laurence K.M., James N., Miller M.H., Tennant G.B., Campbell H. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. Br. Med. J. 1981, 282:1509-1511.
35. Lecomte T., Ferraz J.M., Zinzindohoue F., Loriot M.A., Tregouet D.A., Landi B., Berger A., Cugnenc P.H., Jian R., Beaune P., Laurent-Puig P. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin. Cancer Res. 2004, 10:5880-5888.
36. Loganayagam A., Arenas Hernandez M., Corrigan A., Fairbanks L., Lewis C.M., Harper P., Maisey N., Ross P., Sanderson J.D., Marinaki A.M. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br. J. Cancer 2013, 108:2505-2515.
37. Longley D.B., Harkin D.P., Johnston P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 2003, 3:330-338.
38. Lupo P.J., Dietz D.J., Kamdar K.Y., Scheurer M.E. Gene-environment interactions and the risk of childhood acute lymphoblastic leukemia: exploring the role of maternal folate genes and folic acid fortification. Pediatr. Hematol. Oncol. 2013.
39. Mandola M.V., Stoehlmacher J., Muller-Weeks S., Cesarone G., Yu M.C., Lenz H.-J., Ladner R.D. A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 2003, 63:2898-2904.
40. Mandola M.V., Stoehlmacher J., Zhang W., Groshen S., Yu M.C., Iqbal S., Lenz H.J., Ladner R.D. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 2004, 14:319-327.
41. Marisa L., de Reynies A., Duval A., Selves J., Gaub M.P., Vescovo L., Etienne-Grimaldi M.C., Schiappa R., Guenot D., Ayadi M., Kirzin S., Chazal M., Flejou J.F., Benchimol D., Berger A., Lagarde A., Pencreach E., Piard F., Elias D., Parc Y., Olschwang S., Milano G., Laurent-Puig P., Boige V. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 2013, 10:e1001453.
42. Marsh S., McKay J.A., Cassidy J., McLeod H.L. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int. J. Oncol. 2001, 19:383-386.
43. Mason J.B., Dickstein A., Jacques P.F., Haggarty P., Selhub J., Dallal G., Rosenberg I.H. A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007, 16:1325-1329.
44. Min B.H., Bae J.M., Lee E.J., Yu H.S., Kim Y.H., Chang D.K., Kim H.C., Park C.K., Lee S.H., Kim K.M., Kang G.H. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer 2011, 11:344.
45. Molloy A.M., Daly S., Mills J.L., Kirke P.N., Whitehead A.S., Ramsbottom D., Conley M.R., Weir D.G., Scott J.M. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet 1997, 349:1591-1593.
46. Popat S., Matakidou A., Houlston R.S. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J. Clin. Oncol. 2004, 22:529-536.
47. Powers H.J. Folic acid under scrutiny. Br. J. Nutr. 2007, 98:665-666.
48. Pullmann R., Abdelmohsen K., Lal A., Martindale J.L., Ladner R.D., Gorospe M. Differential stability of thymidylate synthase 3'-untranslated region polymorphic variants regulated by AUF1. J. Biol. Chem. 2006, 281:23456-23463.
49. Sadanandam A., Lyssiotis C.A., Homicsko K., Collisson E.A., Gibb W.J., Wullschleger S., Ostos L.C., Lannon W.A., Grotzinger C., Del Rio M., Lhermitte B., Olshen A.B., Wiedenmann B., Cantley L.C., Gray J.W., Hanahan D. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 2013, 19:619-625.
50. Sanjoaquin M.A., Allen N., Couto E., Roddam A.W., Key T.J. Folate intake and colorectal cancer risk: a meta-analytical approach. Int. J. Cancer 2005, 113:825-828.
51. Sauer H., Wilmanns W. Cobalamin dependent methionine synthesis and methyl-folate-trap in human vitamin B12 deficiency. Br. J. Haematol. 1977, 36:189-198.
52. Scheithauer W., Rosen H., Kornek G.V., Sebesta C., Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993, 306:752-755.
53. Sharp L., Little J. Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am. J. Epidemiol. 2004, 159:423-443.
54. Smulders Y.M., Smith D.E., Kok R.M., Teerlink T., Gellekink H., Vaes W.H., Stehouwer C.D., Jakobs C. Red blood cell folate vitamer distribution in healthy subjects is determined by the methylenetetrahydrofolate reductase C677T polymorphism and by the total folate status. J. Nutr. Biochem. 2007, 18:693-699.
55. Stover P.J. One-carbon metabolism-genome interactions in folate-associated pathologies. J. Nutr. 2009, 139:2402-2405.
56. Taflin H., Wettergren Y., Odin E., Carlsson G., Derwinger K. Gene polymorphisms MTHFRC677T and MTRA2756G as predictive factors in adjuvant chemotherapy for stage III colorectal cancer. Anticancer Res. 2011, 31:3057-3062.
57. Taioli E., Garza M.A., Ahn Y.O., Bishop D.T., Bost J., Budai B., Chen K., Gemignani F., Keku T., Lima C.S., Le Marchand L., Matsuo K., Moreno V., Plaschke J., Pufulete M., Thomas S.B., Toffoli G., Wolf C.R., Moore C.G., Little J. Meta- and pooled analyses of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and colorectal cancer: a HuGE-GSEC review. Am. J. Epidemiol. 2009, 170:1207-1221.
58. Thorn C.F., Marsh S., Carrillo M.W., McLeod H.L., Klein T.E., Altman R.B. PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet. Genomics 2011, 21:237-242.
59. Twelves C., Boyer M., Findlay M., Cassidy J., Weitzel C., Barker C., Osterwalder B., Jamieson C., Hieke K., Xeloda G. Colorectal cancer study, capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur. J. Cancer 2001, 37:597-604.
60. Van Cutsem E., Twelves C., Cassidy J., Allman D., Bajetta E., Boyer M., Bugat R., Findlay M., Frings S., Jahn M., McKendrick J., Osterwalder B., Perez-Manga G., Rosso R., Rougier P., Schmiegel W.H., Seitz J.F., Thompson P., Vieitez J.M., Weitzel C., Harper P. G. Xeloda colorectal cancer study, oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J. Clin. Oncol. 2001, 19:4097-4106.
61. Van Kuilenburg A.B., Vreken P., Beex L.V., Meinsma R., Van Lenthe H., De Abreu R.A., van Gennip A.H. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Eur. J. Cancer 1997, 33:2258-2264.
62. Vignoli M., Nobili S., Napoli C., Putignano A.L., Morganti M., Papi L., Valanzano R., Cianchi F., Tonelli F., Mazzei T., Mini E., Genuardi M. Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil. Pharmacol. Res. 2011, 64:242-248.
63. Wald D.S., Wald N.J., Morris J.K., Law M. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. Bmj 2006, 333:1114-1117.
64. Wallace K., Grau M.V., Levine A.J., Shen L., Hamdan R., Chen X., Gui J., Haile R.W., Barry E.L., Ahnen D., McKeown-Eyssen G., Baron J.A., Issa J.P. Association between folate levels and CpG Island hypermethylation in normal colorectal mucosa. Cancer Prevent. Res. 2010, 3:1552-1564.
65. Wills L., Clutterbuck P.W., Evans B.D. A new factor in the production and cure of macrocytic anaemias and its relation to other haemopoietic principles curative in pernicious anaemia. Biochem J. 1937, 31:2136-2147.
66. Yawata A., Kim S.R., Miyajima A., Kubo T., Ishida S., Saito Y., Nakajima Y., Katori N., Matsumoto Y., Fukuoka M., Ohno Y., Ozawa S., Sawada J. Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents. Cancer Chemother. Pharmacol. 2005, 56:465-472.
67. Yu K., Zhang J., Zhang J., Dou C., Gu S., Xie Y., Mao Y., Ji C. Methionine synthase A2756G polymorphism and cancer risk: a meta-analysis. Eur. J. Hum. Genet.: EJHG 2010, 18:370-378.
68. Zaniboni A. Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival. J. Clin. Oncol. 1997, 15:2432-2441.
69. Zhang C., Wang J., Gu H., Zhu D., Li Y., Zhu P., Wang Y., Wang J. Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: meta-analysis of randomized controlled trials. Oncol. Lett. 2012, 3:831-838.
70. Zhou D., Mei Q., Luo H., Tang B., Yu P. The polymorphisms in methylenetetrahydrofolate reductase, methionine synthase, methionine synthase reductase, and the risk of colorectal cancer. Int. J. Biol. Sci. 2012, 8:819-830.
71. Zintzaras E., Ziogas D.C., Kitsios G.D., Papathanasiou A.A., Lau J., Raman G. MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis. Pharmacogenomics 2009, 10:1285-1294.